Mydecine is an emerging biotech and life sciences company dedicated to developing and commercializing innovative solutions for treating mental health problems and enhancing vitality. The company’s world-renowned medical and scientific advisory board is building out a robust R&D pipeline of nature-sourced psychedelic-assisted therapeutics, novel compounds, therapy protocols, and unique delivery systems. Mydecine has exclusive access to a full cGMP certified pharmaceutical manufacturing facility with the ability to import/export, cultivate, extract/isolate, and analyze active mushroom compounds with full government approval through Health Canada. Mydecine also operates out of a state-of-the-art mycology lab in Denver, CO to focus on genetic research for scaling commercial cultivation of rare (non-psychedelic) medicinal mushrooms.
At the heart of Mydecine’s core philosophy is that Psychedelic-assisted psychotherapy will continue to gain acceptance in the medical community with many of the world’s best accredited research organizations demonstrating its remarkable clinical effectiveness. Mydecine recognizes the responsibility associated with psychedelic-assisted therapy and will continue to position itself as a long-term leader across the spectrum of clinical trials, research, technology, and global supply.
Mydecine is able to oversee all areas of drug development including synthesis, genetic research, import/export, delivery system development, clinical trial execution, product commercialization and distribution.
Seven patent applications that represent thousands of inventions with multiple layers of protection on the company’s proprietary drug development pipeline.
Expert interdisciplinary team and state of the art infrastructure allowing for accelerated drug development process.
Several novel molecule designs by some of the world’s top drug discovery and design experts including Dr. Denton Hoyer formerly with Novartis, Pfizer and Yale as well as the faculty of pharmacology at the University of Alberta.
Phase 2A clinical on PTSD in veterans, EMS and front line workers with test sites currently approved at Leiden University, University Of Alberta, Royal Ottawa Hospital, Western Ontario University and finalizing several VA sites in the United States including Boston, New York, Los Angeles and San Diego.
Large scale microdose study co-sponsored by the National Institute for Health Research at Imperial College of London with Mydecine SAB member Dr. David Erritzoe.
First-of-Its-kind microdose study at Macquarie University in Australia with Mydecine SAB Dr. Vince Polito.
Sponsoring preclinical animal work from University of Maryland aimed at a mechanistic understanding of psilocybin.
Finalizing plans on late stage addiction study.
Mindleap's proprietary digital health platform allows Mydecine to generate revenue in the fast-growing USD $41.4 billion telemedicine market.
Mindleap is a early mover in this emerging market and is focused on expanding services and digital products across conventional mental health treatments to generate revenue as psychedelic therapies get approved.
Mindleap has over 50 Mental Health Providers, combines telemedicine with mental health analytics, is HIPAA/GDPR/PIPEDA compliant, and is available to download on Android & iOS.
Mydecine's partnership with API, enables them to field unparalleled studies with precise control and ownership over study design and drug format. Mydecine utilizes the data both for their own work and to further collaborate with academic leaders in the field.
World Class Research Facility
✓Health Canada Scheduled 1 Drugs and Substances Dealer’s License
✓ 30 + Ph.D.’s, scientists, clinicians, regulatory, patent experts
✓Drug Design, target discover, validation
✓Analytical testing, performance characterization
✓Medicinal chemistry and synthesis
✓School of Pharmacy recognized expertise
✓Ensures clinical study drug supply, all schedule classes
✓Cultivation of psilocybin producing mushrooms
✓Access to hospital network for enablement of clinicalresearch
✓Hundreds of millions of dollars in lab infrastructure
✓Ability to cultivate, extract, conduct R&D, import and export full cGMP certified pharmaceutical grade natural and synthetic psilocybin and other tryptamines